

Welfare & Safety of the Racehorse Summit VII



Dr. Wayne Mcllwraith

Barbara Cox Anthony Endowed University Chair in Orthopaedics, Orthopaedic Research Center Colorado State University

Nutraceuticals (Oral Joint Supplements)

Wayne McIlwraith BVSc, PhD, DACVS, DACVSMR



University Distinguished Professor Barbara Cox Anthony Chair in Orthopaedics Director of Orthopaedic Research Center

Colorado State University

Seventh Welfare and Safety of the Racehorse Summit

Keeneland, Lexington, KY

June 18, 2016

GRAYSON-JOCKEY CLUB RESEARCH FOUNDATION, INC.

Welfare and Safety of the Racehorse Summit

RESEARCH CENTER

Disclosures

- Consultant for Arthrex & PulseVet
- Shareholder in Advanced Regenerative Therapies (ART)
- Director ANZAC
- Research funding from
 - **IDEXX**
 - Bayer
 - Luitpold
 - Arthrex
 - Orthogen
 - PulseVet
 - VetStem
 - Merial

Other research funded by independent agencies

Osteoarthritis (OA)

Single most common lameness in horses

Clegg & Booth Practice 2000

- Horse population in US estimated \$7.3 million & therefore millions of horse have this debilitating condition
- OA similarly important in humans affecting at least 20 million Americans with incidence expected to double over next in next 2 decades

Osteoarthritis (OA)

- Oral joint supplements (OJSs) are a common choice of clients and have been perceived as a benign treatment for OA in horses
- The high prevalence of OA combined with the lack of a definitive cure has probably contributed to the popularity of OJSs
- Side effects of NSAIDs & corticosteroids an argument as well

Stages of OA in a Hgh Motion Joint Normal Joint

Stage 1 OA

 Synovitis and no morphologic change in articular cartilage

Stage 2 OA

Synovitis less acute
 Morphologic damage in articular cartilage commencing

Stage 3 OA

Synovitis chronic
 Morphologic damage in articular cartilage severe

Stage 4 OA

Synovitis chronic
Full thickness loss of articular cartilage

Factors Involved in Degradation of Articular Matrix

University

Goal of treatment in all traumatic joint entities

- Return the joint to normal as quickly as possible
- Prevent the occurrence or reduce the severity of OA In other words:
- Reduce pain and minimize progression of joint deterioration
 - Symptom modifying OA Drugs (SMOADs)
 - Disease modifying OA drugs (DMOADs)
- Timely removal of osteochondral fragments, fixation of IA fractures, accurate diagnosis of ligamentous & meniscal injuries & appropriate treatment of OCD entities are also critical treatments to prevent OA

We Evaluate Effectiveness of Treatments using Two Griteria with in vivo Studies Symptom modifying effects (SMOADs) Improvement in clinical signs Disease modifying effects (DMOADs) Proof that progressive OA disease is modified Ideally we want both but second is critical and valuable long term

Treatments of Traumatic Arthritis & OA Evaluated in Controlled Studies

- Physical therapy and rehabilitation
- Extracorporeal shock wave therapy
- NSAIDs
- IA corticosteroids
- IA HA
- IV HA
- Oral HA
- IA PSGAG
- IM PSGAG
- IM Pentosan polysulfate
- Oral joint supplements (nutraceuticals)
- Anti-cytokine therapy (protein or gene therapy)
- Platelet rich plasma
- Mesenchymal stem cells

Ntraceuticals (Oral Joint Supplements)

Where do they fit in all this?

- Not usually prescribed specifically by a veterinarian
 Common choice of clients & have been perceived as a benign treatment for OA in horses
 - **Trumble TN. The use of nutraceuticals for osteoarthritis in horses.** North Am Vet Clin Equine Pract 2005

Gritical Components of Articular Cartilage Also Need to be Maintained

- 'Joint maintenance' a common indicationType II collagen
- Extracellular matrix
 - Proteoglycans
 - Water

McIlwraith CW (2013) Oral joint supplements in the management of osteoarthritis In Geor, Harris & Coenen et al (eds) Equine Applied and Clinical Nutrition

Editol by RAYMOND J. GEOR Brin, Inth. Publiched ACMI dauge Annuel, Dyna RATRICHA & HARRIS NA, Publiched Discussion ECOL Volte, NRDM MANERED COENEN Pur, Drand van, Bijdenen ECOL

Oral Joint Supplements (OJSs)

- High prevalence of OA in combination with lack of definitive cure has probably contributed to popularity of OJSs
- Most popular types of nutritional supplements for horses (half of all equine supplements sold in US)
- Estimated that 49% of all horse owners use
 - Packaged Facts 2008 <u>www.packaged</u> facts.com/petsupplements-market-c1641

Indications for Oral Joint Supplements

OJSs are fed to horses for one of two purposes:

- To treat lame horses and make chronically unsound horses sound..this use is flawed because often the source of lameness is never diagnosed when the owner or trainer elects to use supplements without consulting a veterinarian
- OR
- To prevent/delay the development of joint problems..hard to prove/disprove but is basis for high use of im Adequan® & iv Legend® as well as OJSs

Mechanisms for development of OA&possible mechanisms of action for OJSs in mitigating these processes – mainly derived from in vitro data

McIlwraith CW (2013)

Types of Oral Joint Supplements

- Majority include glucosamine (GU) and/or chondroitin sulfate (CS) along with other added ingredients
- May also contain additional ingredients including manganese, vitamin C, hyaluronic acid or HA, polyunsaturated fatty acids (PUFAs), rare earth minerals, unsaponified avocado soy (ASU), green lipped muscle (Perna canaliculus), cetylmyristoleate, methylsulfonylmethane, & various herbs with exception of last two (no good equine documentation) we will discuss these various products

Oral nutraceuticals-marketing with little control is a issue

COUNT ON COSEQUIN It can be your "competitive edge".

Keeping your horses sou through the rigos of taining a competition can be a tryit experience. How many yeads never even get through their rear of training? And how many promit reappacts jut don't gute make it to the top?

Regardless of age or conditioning. He sites it parsing and competition coules were and lear to joint coatilage, and con ultimately components the performance of our equine sites. Coessuir plays on insolution takes instants. The bady needs to replenish the components of the costinge matk. Unlike eleroids and some NGAD's which can charally cause domage to the continge abla, caused domage to the continge straceutical with unparalleled safety. Straceutical with unparalleled safety. Service Some class to motching the ontidence and reliability of the clean, alerede formulation that has helped make

> w Cosequin' is even more cost with a new manufacturing proces uces a more consistent powder source dosing, and a new 700 gram with 30% more active ingredients cost

ut for yourself why so many owners en selv on Cosequin — It can be your filve edge". re information or to order Cosequin', ct your velgenation or call tol-free

Official nu the U.S. Ec Inappropriate advertising is an issue

Some FDA letters but 'joint formula' & 'promoting joint health' insinuate therapeutic effects

Through Fine Veterinar

the Most Potent Joint Formula on the Planet

(+HCI/-2KCISO4/+NaCISO4/NAD)

Super Savings Visit our Booth

Oral Joint Supplements

- None of the oral supplements or oral nutraceuticals are licensed
- Most products include glucosamine and/or chondroitin sulfate along with other added ingredients
- Initial products for horse:
 - **CS** product from bovine trachea (Flex-Free®
 - **Complex of GAGs and other nutrients from the sea mussel** *Perna canaliculus* (SynoFlex®)
- Cosequin[®] combination of glucosamine (GU), CS, manganese, and vitamin C
- Number of other products followed simulating Cosequin®

In vitro dose titration studies of GU&CS alone & in combination with equine cartilage explants

- Decreased GAG loss into medium with higher (of GU, CS and GU+CS
- Intermediate doses enhanced GAG synthesis and total cartilage GAG content

Dechant, Baxter, Frisbie et al Equine Vet J 2005

Effects of glucosamine hydrochloride and chondroitin sulphate, alone and in combination, on normal and interleukin-1 conditioned equine articular cartilage explant metabolism

J. E. DECHANT*, G. M. BAXTER, D. D. FRISBIE, G. W. TROTTER and C. W. McILWRAITH

Equine Orthopaedic Research Laboratory, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado 80523, USA.

Same dosages tested on IL-1 conditioned explants

- No treatment effects for GU or CS alone
- Protective effect for GU+CS for total GAG release into the media
- How does it relate to concentrations achieved with oral administration?

Effects of glucosamine hydrochloride and chondroitin sulphate, alone and in combination, on normal and interleukin-1 conditioned equine articular cartilage explant metabolism

J. E. DECHANT*, G. M. BAXTER, D. D. FRISBIE, G. W. TROTTER and C. W. McILWRAITH

Equine Orthopaedic Research Laboratory, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado 80523, USA.

What about absorption compared to in vitro levels that are efficacious?

- Chondroitin sulfate yes low molecular weight CS (0.80 kD) absorbed to a greater degree than GU; absorption may be influenced by MW
 Du et al *Biopharm Drug Dispos* 2002
 Glucosamine not in sufficient levels
 - Laverty et al Arthritis Rheum 2004
- Still does not prove effectiveness in the horse

Serum GAG & HA levels Do Not Reflect Absorption as has been Gaimed Both marker of inflammatory joint disease

Cinical Trials

In a review of 15 in vivo equine studies, authors signaled an encouraging trend: manufacturers of these products are investing in research, but most do not meet a quality standard that provided sufficient confidence in the results reported. Consequently, the overall level of evidence for in vivo demonstration of efficacy is weak.

706

EQUINE VETERINARY JOURNAL Equine vet. J. (2009) **41** (7) 706-712 doi: 10.2746/042516409X424153

Review Article

Low quality of evidence for glucosamine-based nutraceuticals in equine joint disease: Review of *in vivo* studies

Gucosamine/chondroitin Arthritis Intervention Trial (GAIT)

Knee pain

- Placebo
- GS
- CS
- **GS+CS**
- Celecoxib
- 1583 randomized & 1258 (80%) completed study
 - No significant improvement in knee pain versus placebo was seen in supplement group but improvement with celecoxib
 - In subset with moderate to severe knee pain some improvement seen

Daniel O. Clegg, M.D., Domenic J. Reda, Ph.D., Crystal L. Harris, Pharm.D., Marguerite A. Klein, M.S., James R. O'Dell, M.D., Michele M. Hooper, M.D., John D. Bradley, M.D., Cliffon O. Bingham III, M.D., Michael H. Weisman, M.D., Christopher G. Jackson, M.D., Nanoy E. Lane, M.D., John J., Cush, M.D., Larry W. Moreland, M.D., H. Ralph Schumacher, Jr., M.D., Chester V. Oddis, M.D., Frederick Wolfe, M.D., Jerry A. Molitor, M.D., David E. Yocum, M.D., Thomas J. Schnitzer, M.D., Daniel E. Furst, M.D., Allen D. Sawitzke, M.D., Helen Shi, M.S., Kenneth D. Brandt, M.D., Roland W. Moskowitz, M.D., and H. James Williams, M.D.

Sasha's Blend

- NZ green-lipped mussel, shark cartilage, abalone & a lipid extract from *Biota orientalis* = Sasha's EQ Powder (SEO)
- **Decreased IL-1**βinduced PGE2 in vitro
- Evaluated by feeding horses SEO at different doses with placebo group & injected one carpus with IL-1β& one with saline.
- SEO significantly inhibited increased PGE2 & GAG levels with IL-1β

Pearson et al Mol.Nutr.Food.Res. 2007;51:1020-1030

Oral Hyaluronan

- Anecdotal support for effectiveness
- A number of products (two developed by veterinarians)
 - **Conquer**
 - Lubrisyn®
- Anecdotal reports of benefit in OA

Evidence for efficacy of oral hyaluronan

• Oral HA (ConquerTM) given after arthroscopic surgery for tarsocrural OCD

- 27 joints (24 yearlings) treated with 100 mg orally for 30 days postop
- 30 joints (24 yearlings) treated with placebo orally for 30 days
- Blinded examiner scored effusion at 30 days (grade 0-5)
- Mean 30 day effusion score treated group 0.67 in treated group and 2.05 in placebo group (p<0001)</p>
 - Bergin et al Equine Vet J 2006; 38:375-378

EQUINE VETERINARY JOURNAL Equine vet. J. (2006) 38 (4) 375-378

Oral hyaluronan gel reduces post operative tarsocrural effusion in the yearling Thoroughbred

B. J. BERGIN*, S. W. PIERCE, L. R. BRAMLAGE and A. STROMBERG[†]

Rood and Riddle Equine Hospital, PO Box 12070, Lexington, Kentucky, 40580-2070, USA. [†]Department of Statistics, University of Kentucky, Lexington, Kentucky 40506-0027, USA.

375

Extract of Green-lipped Mussel (*Perna* canaliculus)

- Randomized, double-blinded placebo controlled study in horses with clinical cases [chronic fetlock lameness (OA)]
- 19 treated & 20 placebo 56 days
- Significant reduction in severity of lameness (p<0.001), reduced joint pain (p<0.014), & improved response to joint flexion (p<0.001)

Equine Veterinary

A randomised, double-blinded, placebo-controlled study on the efficacy of a unique extract of green-lipped mussel (*Perna canaliculus*) in horses with chronic fetlock lameness attributed to osteoarthritis

J. CAYZER*, D. HEDDERLEY' and S. GRAY'

Estendart Ltd, Massey University, Private Bag, Palmerston North, New Zealand; 'The NZ Institute for Plant and Food Research Ltd, Food Industry Science Centre, Fitzherbert Science Centre, Private Bag, Palmerston North, New Zealand; and 'Samantha Gray Consulting, Auckland, New Zealand.

Avocado Soy Unsaponified (ASU)

- Vetoquinol ASU studied in equine OA model
- First controlled equine study demonstrating a positive effect with an oral nutraceutical → disease-modifying effects
- Controlled studies in humans also positive

Evaluation of avocado and soybean unsaponifiable extracts for treatment of horses with experimentally induced osteoarthritis

Christopher E. Kawcak, DVM, PhD; David D. Frisbie, DVM, PhD; C. Wayne McIlwraith, BVSc, PhD; Natasha M. Werpy, DVM; Richard D. Park, DVM, PhD

Equine Study with ASU(Luxovan®)

- Two treatment groups (8 horses in each)
- Osteochondral fragment model
- Gp 1 : ASU with sweet feed. Administered orally once a day from day 0-72
- Gp 2 : Sweet feed. Administered orally once a day from day 0-72

Evaluation of avocado and soybean unsaponifiable extracts for treatment of horses with experimentally induced osteoarthritis

Christopher E. Kawcak, DVM, PhD; David D. Frisbie, DVM, PhD; C. Wayne McIlwraith, BVSc, PhD; Natasha M. Werpy, DVM; Richard D. Park, DVM, PhD

Synovitis-04

16 Horses

8 Horses

Chip

Univers

No Chip

ASU

No Chip

Chip

Plac

Horses

Placebo

Outcome Parameters

- Lameness pre- & post-flexion every 2 weeks
- Radiographs prior to surgery & at study conclusions
 - Changes in subchondral bone & osteophytosis
- Synovial fluid once a week
- Serum once a week
- Treadmill exercise days 15 72 (5 days a week : 2 minutes trot, 2 minutes gallop, 2 minutes trot)
- Gross necropsy
- Histopathology
 - **Synovial membrane**
 - Articular cartilage
- Articular cartilage biochemistry
 - GAG content
 - GAG synthesis

Intimal Hyperplasia

Cartilage disease score

ASUin the Hbrse

- Significant reduction in severity of articular erosion & synovial hemorrhage compared to placebo-treated horses
- Significant increase in articular cartilage glycosaminoglycan synthesis compared to placebo treated horses

Other companies have product with ASU (different than Vetoquinol product)

1300 Grams of Tasty Powder

U.S. Patent Nos. 5,587,363 and 6,797,289 Additional Patent Pending

Available only through veterinarians.

2208 Lakeside Boulevard Edgewood, Maryland 21040 1-800-925-5187 cosequinequine.com

Polyunsaturated Fatty Acids (PLFAs)

- Omega-3 (n-3) PUFAs contain α-linolenic acid that is desaturated in body to produce eicosapentaenoic acid & docosahexaenoic acid analogs of arachidonic acid
- Found in oily fish & fish oils
- Decrease production of inflammatory cytokines, prostaglandins, aggrecanases, thromboxanes, leukotrienes, reactive oxygen species

Aggrecanase is an important target in joint inflammation

- reIL-1βin carpal joints
- Expression of deleterious mediators
- ADAMTS-4 (aggrecanase-1) increased in synovial membrane
- ADAMTS-4 &-5 (aggrecanase-1&-2) increased in articular cartilage

0 (2012) 1583-1590

Evaluation of the inflammatory response in experimentally induced synovitis in the horse: a comparison of recombinant equine interleukin 1 beta and lipopolysaccharide

T.N. Ross † ‡, J.D. Kisiday †, T. Hess ‡, C.W. McIlwraith †* 1 Papartment of Clinical Sciences and Call Holms Equine Orthopadic Research Center, Colorado Stare University, Fort Collins, CO 80523, USA 1 papartment of Annal Science, Colorado State University for Collins, CO 80523, USA

In vivo Study of PUFAs in Equine Joint Inflammation

- Lower expression of aggrecanase-1 in inflamed synovial membrane
- Modest decrease in activity of other mediators..real therapeutic value still to be proven

Journal of Animal Physiology and Animal Nutrition

DOI: 10.1111/jpn.12359

ORIGINAL ARTICLE

Influence of an *n-3* long-chain polyunsaturated fatty acidenriched diet on experimentally induced synovitis in horses

T. N. Ross-Jones¹, C. W. McIlwraith², J. D. Kisiday², T. M. Hess¹, D. K. Hansen¹ and J. Black^{1,2}

1 Department of Animal Science, Colorado State University, Fort Collins, CO, USA, and 2 Gail Holmes Equine Orthopaedic Research Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO, USA

PUFAs have been incorporated into some OJSs

- Rare earth minerals
- Omega 3 fatty acids
- Scientific support for n-3 fatty acids
 - Inhibit aggrecanase
 - Inhibit COX2 & 5- lipooxygenase
 - Inhibit autocrine synthesis of IL-1 & TNF-α
- A different type of nutraceutical
- Getting studied in horse

Osteoarthritis and Cartilage (2009) 17, 896–905 Crown Copyright © 2009 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International. All rights reserved. doi:10.1016/j.joca.2008.12.009

Relative efficacies of omega-3 polyunsaturated fatty acids in reducing expression of key proteins in a model system for studying osteoarthritis

Z. Zainal^a, A. J. Longman, S. Hurst, K. Duggan, B. Caterson, C. E. Hughes* and J. L. Harwood School of Biosciences, Cardiff University, Cardiff CF10 3AX, UK

Cetyl Myristoleate (CM)

- Another fatty acid..ester of myristoleic acid
- CM mat act by inhibition of 5-lipooxygenase pathway
- Product containing CM, GU, MSM & hydrolyzed collagen (Myristol[™]) evaluated in blind controlled study with 39 horses
- Myristol group improved significantly more than placebo group in AAEP lameness score, VAS, response to flexion, lameness after flexion

Effects of an Oral Nutraceutical on Clinical Aspects of Joint Disease in a Blinded, Controlled Clinical Trial: 39 Horses

Kevin G. Keegan, DVM, MS, Diplomate ACVS; Faith E. Hughes, DVM, Diplomate ACVS; Tom Lane, DVM; Frances C. Buonomo, PhD; and Judy Downer, PhD

Can Supplements Strengthen Bone?

- Platinum Performance
 - Rare earth minerals that involved in bone metabolism
- OCD Pellets
 - Contain HA, silicon dioxide, amino acids, vitamins, microsized isolates
 - Silicon been shown to increase bone density

Further Reading

Edited by

RAYMOND J. GEOR BVSc, MVSc, PhD, Diplomate ACVIM (Large Animal), Diplomate ACVSMR, Diplomate ACVN (Honorary)

PATRICIA A. HARRIS MA, PhD, Diplomate ECVCN, VetMB, MRCVS

MANFRED COENEN Prof., Dr. med. vet., Diplomate ECVCN

Foreword by HRH Princess Anne

Edinburgh London New York Oxford Philadelphia St Louis Sydney Toronto 2013

